ciprofloxacin has been researched along with Viremia in 5 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Viremia: The presence of viruses in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 9.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| " The purpose of the current study was to evaluate the safety and efficacy of ciprofloxacin for the prevention of BK viremia in kidney transplant recipients." | 5.30 | Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. ( Gaber, AO; Graviss, EA; Knight, RJ; Kuten, SA; Moore, LW; Musick, WL; Nguyen, DT; Patel, SJ, 2019) |
| "This analysis demonstrates for the first time that, used in a stepwise fashion, ciprofloxacin and leflunomide are effective and safe treatments for BK viremia in PRTR." | 3.80 | A novel treatment regimen for BK viremia. ( Cheam, H; Ettenger, RB; Malekzadeh, MH; Tsai, EW; Zaman, RA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, SJ | 1 |
| Knight, RJ | 1 |
| Kuten, SA | 1 |
| Graviss, EA | 1 |
| Nguyen, DT | 1 |
| Moore, LW | 1 |
| Musick, WL | 1 |
| Gaber, AO | 1 |
| Umbro, I | 1 |
| Anzivino, E | 1 |
| Tinti, F | 1 |
| Zavatto, A | 1 |
| Bellizzi, A | 1 |
| Rodio, DM | 1 |
| Mancini, C | 1 |
| Pietropaolo, V | 1 |
| Mitterhofer, AP | 1 |
| Zaman, RA | 1 |
| Ettenger, RB | 1 |
| Cheam, H | 1 |
| Malekzadeh, MH | 1 |
| Tsai, EW | 1 |
| Gagneux-Brunon, A | 1 |
| Pillet, S | 1 |
| Laurent, B | 1 |
| Mariat, C | 1 |
| Michalet, M | 1 |
| Lucht, F | 1 |
| Botelho-Nevers, E | 1 |
| Halim, MA | 1 |
| Al-Otaibi, T | 1 |
| El-Kholy, O | 1 |
| Gheith, OA | 1 |
| Al-Waheeb, S | 1 |
| Szucs, G | 1 |
| Pacsa, A | 1 |
| Balaha, MA | 1 |
| Hasaneen, H | 1 |
| Said, T | 1 |
| Nair, P | 1 |
| Nampoory, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203] | Phase 4 | 200 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study[NCT02758288] | 0 participants (Actual) | Observational | 2015-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 31 |
| Placebo | 8 |
Clostridium difficile infection at 6 months (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 0 |
Patient death at 1 year (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 1 |
| Placebo | 1 |
First BK plasma viral loads (NCT01789203)
Timeframe: 12 months
| Intervention | copies/mL (Median) |
|---|---|
| Ciprofloxacin | 2514 |
| Placebo | 1423 |
kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 14 |
| Placebo | 7 |
Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 25 |
| Placebo | 5 |
Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 3 |
| Placebo | 2 |
Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 17 |
| Placebo | 14 |
Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 15 |
| Placebo | 7 |
Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 35 |
| Placebo | 18 |
Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months
| Intervention | days (Median) |
|---|---|
| Ciprofloxacin | 90 |
| Placebo | 76.5 |
1 trial available for ciprofloxacin and Viremia
| Article | Year |
|---|---|
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial.
Topics: Adult; BK Virus; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Humans; Immunosuppres | 2019 |
4 other studies available for ciprofloxacin and Viremia
| Article | Year |
|---|---|
Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences.
Topics: Adult; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; DNA, Intergenic; DNA, Viral; Humans; Kidney T | 2013 |
A novel treatment regimen for BK viremia.
Topics: Adolescent; BK Virus; Child; Ciprofloxacin; Female; Fluoroquinolones; Glomerular Filtration Rate; Hu | 2014 |
A case of BK virus nephropathy in a stem cell transplant recipient: a rare or under-recognized cause for Acute Kidney injury.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; Cord Blood Stem Cell Transplant | 2015 |
Active management of post-renal transplantation BK virus nephropathy: preliminary report.
Topics: Adult; Anti-Infective Agents; Biopsy; BK Virus; Ciprofloxacin; Creatinine; Female; Histocompatibilit | 2009 |